

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)

March 10-14, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Scientific Organizers: Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege

Sponsored by Autolus Therapeutics

Abstract & Scholarship Deadline: November 7, 2018 / Abstract Deadline: December 5, 2018 / Discounted Registration Deadline: January 15, 2019

SUNDAY, MARCH 10

Arrival and Registration

MONDAY, MARCH 11

Welcome and Keynote Address

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Driving Anti-Tumor Responses with Neoantigen Vaccines

Response and Resistance Mechanisms to Cancer Immunotherapy

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy

Philip D. Greenberg, University of Washington, USA
Resistance Mechanisms to Engineered T Cell Therapies

Shannon J. Turley, Genentech, Inc., USA
Overcoming Inhibitory Pathways in the Tumor Microenvironment

Short Talk(s) Chosen from Abstracts

Technological Advances for Dissecting Immune Responses

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Evaluating Tumor Antigen-Specific T Cell Responses

Michael Angelo, Stanford University, USA
Visualization of Tumor-Immune Components

Aviv Regev, Massachusetts Institute of Technology/Broad Institute, USA
Comprehending Anti-Tumor Immune Responses through Single-Cell Studies

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 12

Improving Anti-Tumor Immune Responses

Chris Takimoto, Forty-Seven, USA
Enhancing Antitumor Immunity by Inhibiting CD47 Signaling

Elizabeth G. Trehu, Jounce Therapeutics, USA
Lessons Learned from Clinical Trials Targeting ICOS

Thomas Gajewski, University of Chicago, USA
Initiating Anti-Tumor Immune Responses with STING Agonist

Speaker to be Announced
Epigenetics or Metabolism

Short Talk(s) Chosen from Abstracts

Engineering T Cells

Crystal L. Mackall, Stanford University, USA
Next Generation CAR T Cells

Kristen Hege, Celgene, USA
Clinical Development of BCMA CAR-T Cells in Myeloma

Carl H. June, University of Pennsylvania, USA
CAR T Cell Therapies: Lessons Learned and Next Steps

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 13

Immune Checkpoints: Basic Mechanisms and Novel Targets

James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Therapy: Lessons Learned and Next Steps

Lisa M. Coussens, Oregon Health & Science University, USA
Evaluating Myeloid Targets to Enhance Anti-Tumor Immune Responses

Speaker to be Announced
BITE

Speaker to be Announced
Oncolytic Viral Therapies

Short Talk(s) Chosen from Abstracts

Combinatorial Immunotherapy Strategies

Sandra Demaria, Weill Cornell Medical College, USA
Combining Immunotherapy with Radiation Therapy

Juan C. Jaen, Arcus Biosciences, USA
Targeting Immune Activation via Inhibition of the Adenosine Pathway

Antoni Ribas, University of California, Los Angeles, USA
Novel Combination Therapy Strategies

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 14

Progress Report on Immune Monitoring and Clinical Trials

Robert H. Vonderheide, University of Pennsylvania School of Medicine, USA
Novel Immunotherapy Strategies that Effectively Treat Patients with Pancreatic Cancer

Dana Pe'er, Memorial Sloan Kettering Cancer Center, USA
Novel Methods for Evaluating Immune Responses

Speaker to be Announced
Prostate Cancer or GBM

Speaker to be Announced
Managing Toxicities

Short Talk(s) Chosen from Abstracts

The Future of Cancer Immunotherapy

Jennifer Ann Wargo, University of Texas MD Anderson Cancer Center, USA
Microbiome Targeting and Future Strategies to Improve Cancer Immunotherapy

Michael C. Jensen, University of Washington School of Medicine/Fred Hutchinson Cancer Research Center, USA
From Good to Great: Next Iterative Steps for CAR T Cell Therapy of Childhood Leukemia

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)

March 10-14, 2019 • Whistler Conference Centre • Whistler, British Columbia, Canada

Scientific Organizers: Padmanee Sharma, Aviv Regev, Crystal L. Mackall and Kristen Hege

Sponsored by Autolus Therapeutics

Abstract & Scholarship Deadline: November 7, 2018 / Abstract Deadline: December 5, 2018 / Discounted Registration Deadline: January 15, 2019

Speaker to be Announced

Bispecific Checkpoint Antibodies and T Cell Engagers

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, MARCH 15

Departure